Table 1.

Registered clinical studies regarding the application of MSCs in patients with ARDS

ClinicalTrials.gov identifier	Study title	Study phase	Actual/estimated enrollment	Cell source	Cell does	Primary outcome	Location	Status
NCT01775774	Human mesenchymal stem cells for acute respiratory distress syndrome (START)	Phase 1	9 participants	Bone marrow MSCs	1 × 106,5 × 106, and 10 × 106 cells/kg	Infusion associated adverse events	USA	Completed
NCT03608592	Human umbilical cord-derived mesenchymal stem cells therapy in acute respiratory distress syndrome	Phase 1	12 participants	Umbilical cord-derived MSCs	1 × 106 cells	Infusion associated events	China	Not yet recruiting
NCT02804945	Mesenchymal stem cells (MSCs) for treatment of acute respiratory distress syndrome (ARDS) in patients with malignancies	Phase 1	20 participants	Bone marrow MSCs	3 × 106/cells/kg	Adverse events	USA	Active, not recruiting
NCT01902082	Adipose-derived mesenchymal stem cells in acute respiratory distress syndrome	Phase 1	20 participants	Adipose-derived MSCs	1 × 106/cells/kg	Adverse events	China	Completed
NCT02444455	Human umbilical-cord-derived mesenchymal stem cell therapy in acute lung injury (UCMSC-ALI)	Phase 1/2	20 participants	Human umbilical cord MSCs	5 × 105/cells/kg	Major adverse events	China	Recruiting
NCT02112500	Mesenchymal stem cell in patients with acute severe respiratory failure (STELLAR)	Phase 2	10 participants	Bone marrow MSCs	Unclear	Oxygen index at 3 days after MSCs infusion	Korea	Unknown
NCT03042143	Repair of acute respiratory distress syndrome by stromal cell administration (REALIST)	Phase 1/2	75 participants	Umbilical cord-derived MSCs	Unclear	Oxygenation index, serious adverse events	UK	Recruiting